SFB 1074: Experimental Models and Clinical Translation in Leukemia

点击翻译按钮获取中文摘要

In recent years, there has been enormous progress in characterizing genetic drivers in leukemogenesis, followed by the successful clinical development of molecular therapies. Collaborative Research Center (CRC) 1074 has anticipated and accompanied this development from the very beginning. CRC 1074 has aimed at bridging basic, translational and (pre)clinical research in the field of leukemia, focusing on translating insights into the pathogenesis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) into new therapies.The structure of CRC 1074 consists of two closely interacting Project Groups: Group A projects with the expertise in experimental models of leukemogenesis, and Group B projects focusing on translational / preclinical leukemia research. Here, CRC 1074 has the privilege to benefit from most visible clinical research in leukemia and unique biobanks of the national leukemia study groups located at Ulm University, belonging to the largest clinically and molecularly annotated collections worldwide. The individual projects are complemented by two core projects, the Bioinformatics/Single-Cell Sequencing Core (Z1) and the Mass Spectrometry and Proteomics Core (Z3). In the grant renewal proposal, seven new principal investigators have been integrated, five of them being young female scientists with an outstanding record, at different stages of their career. Furthermore, CRC 1074 has integrated two research groups from the German Cancer Research Center in Heidelberg, and one group from Charité University Medicine Berlin, based on their specific expertise and on already long-standing collaborations.We expect that a third funding period of CRC 1074 will further successfully strengthen the international visibility of basic and translational leukemia research at Ulm University and continue to provide major scientific contributions. The invaluable resources of CRC 1074 will facilitate translating research findings into clinical practice and ultimately improve care of patients with leukemia.